Tragara Pharmaceuticals today announced that its abstract has been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held from April 18-22, 2009, in Denver, Colorado. The presentation will disclose the results of Tragara’s Phase I study of apricoxib in combination with erlotinib in non-small cell lung cancer. The abstract can be accessed through the AACR website, www.aacr.com. The abstract title and presentation time is provided below; however, please note that according to AACR policy, all data is embargoed until the time of the beginning of the presentation.

Abstract # 5621 (April 22, 09:25 – 09:40 AM; Room 702-706): Biomarker based phase I study of Apricoxib, a potent COX-2 inhibitor in combination with erlotinib in small-cell lung cancer (NSCLC) patients.

The event will take place July 22nd, 2009 from 5:00p - 7:00p.